Lumenis Introduces the New Pulse(TM) 100H and Pulse(TM) 50H Holmium Laser Systems* Designed to Treat Any Size of Prostate and Any Size and Type of Stone
(Thomson Reuters ONE) -
Expanding Its Comprehensive Urology Portfolio, Lumenis Debuts Two Innovative
Laser Systems for the Treatment of BPH and Stones
LONDON, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (NASDAQ:LMNS), the world's
largest energy-based medical device company for surgical, aesthetic and
ophthalmic applications, announced the launch of Lumenis Pulse(TM) 100H and
Lumenis Pulse(TM) 50H at the 33(rd) World Congress of Endourology (WCE), taking
place October 1 - 4, 2015 in London, UK.
Photos accompanying this release are available at
http://www.globenewswire.com/newsroom/prs/?pkgid=36578
http://www.globenewswire.com/newsroom/prs/?pkgid=36579
The Lumenis Pulse 100H, the next generation of the VersaPulse® PowerSuite(TM)
100 Watt system, is a versatile and enhanced laser solution for the treatment of
a wide array of clinical urologic indications including benign prostatic
hyperplasia (BPH), stones, tumors or strictures, along with a range of other
specialties such as general surgery, ENT, gynecology and pulmonary surgery. As a
greatly effective laser system for stones and BPH, the Pulse 100H enables users
to perform holmium laser enucleation of the prostate (HoLEP), the gold standard
treatment for BPH, and stone dusting(TM).
The new system features an improved design to enhance patient safety and overall
user experience. It offers a robust combination of laser parameters addressing
more than 70 types of procedures, an innovative pulse reshape function for
improved safety, dual pedals for improved ease of use, a hands-free ready and
standby mode for minimizing cost per procedure, and a high energy per pulse of
up to 3.5J with a high repetition rate of up to 50Hz.
In addition to the Pulse 100H, Lumenis will also be unveiling another key
addition to the Lumenis Pulse laser family, the Pulse 50H laser system. Designed
to efficiently address any type or size of stone in lithotripsy, the Pulse 50H
system is a superior comprehensive solution that provides 0.2J of energy per
pulse to minimize migration of even the smallest stone. Furthermore, the Pulse
50H can be later upgraded to the new Pulse 100H, allowing physicians to further
leverage their investment as they grow their practice.
"The new Pulse 50H system provides all features to perform modern intra
corporeal Holmium laser lithotripsy including a wide range of energy levels and
frequencies," said Professor Rassweiler, M.D., Ph.D., Klinikum SLK, Heilbronn-
Germany.
"With our commitment to the Endourological Society, we are proud to present two
new innovative systems, the Pulse 100H and 50H, to meet the developing, dynamic
market need in the field of minimally invasive urological surgery," said Tzipi
Ozer-Armon, CEO of Lumenis. "The additions to the Pulse platform series signify
a key improvement to our current urological solutions for HoLEP and stone
dusting and empower users to achieve more than 70 types of procedures in a range
of clinical specialties."
To learn more about the Lumenis Pulse 100H and 50H from leading clinical
experts, please visit the company's booth # 411 during the following times:
Friday, October 2
14:00 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber
Speaker: Dr. Mark E. Leo, US
15:00 HoLEP vs. TURP: A Cost Analysis
Speaker: Mr. Mark Cynk, UK
15:45 Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible
Ureteroscopy
Speaker: Dr. Marc Beaghler, US
16:30 HoLEP Technique Improvements with the New Lumenis Pulse 100H
Speaker: Mr. Gerald Rix, UK
17:15 HoLEP Technique Improvements with the New Lumenis Pulse 100H
Speaker: Mr. Gerald Rix, UK
Saturday, October 3
13:00 Lumenis' Pulse 120H and the New SlimLine 200 D/F/L for Flexible
Ureteroscopy
Speaker: Dr. Marc Beaghler, US
13:45 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber
Speaker: Dr. Mark E. Leo, US
14:15 HoLEP vs. TURP: A cost analysis
Speaker: Mr. Mark Cynk, UK
15:00 Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases
Speaker: Prof. Jens Rassweiler, Germany
15:45 Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible
Ureteroscopy
Speaker: Dr. Marc Beaghler, US
16:30 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber
Speaker: Dr. Mark E. Leo, US
Sunday, October 4
09:00 Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible
Ureteroscopy
Speaker: Dr. Marc Beaghler, US
10:00 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber
Speaker: Dr. Mark E. Leo, US
10:45 Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases
Speaker: Prof. Jens Rassweiler, Germany
11:30 Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases
Speaker: Prof. Jens Rassweiler, Germany
13:00 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber
Speaker: Dr. Mark E. Leo, US
* The Lumenis Pulse 100H and Lumenis Pulse 50H are not yet available in the
United States.
About Lumenis
Lumenis (NASDAQ:LMNS) is a global leader in the field of minimally-invasive
clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is
a world-renowned expert in developing and commercializing innovative energy-
based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-
Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have
redefined medical treatments and have set numerous technological and clinical
gold-standards. Lumenis has successfully created solutions for previously
untreatable conditions, as well as designed advanced technologies that have
revolutionized existing treatment methods. For more information
visit: www.lumenis.com
Forward-Looking Statements
Information provided in this press release may contain statements relating to
current expectations, estimates, forecasts and projections about future events
that are "forward-looking statements" as defined in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements may include but
are not limited to the Company's plans, objectives and expectations for future
operations, including its projected results of operations. Forward-looking
statements are often characterized by the use of forward-looking terminology
such as "may," "will," "expect," "anticipate," "estimate," "continue,"
"believe," "should," "intend," "plan," "project" or other similar words, but are
not the only way these statements are identified. These forward-looking
statements are based upon our management's current estimates and projections of
future results or trends. Actual results may differ materially from those
projected as a result of certain risks and uncertainties, including those risks
discussed under the heading "Risk Factors" in our most recent Annual Report on
Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-
looking statements are made only as of the date hereof, and the Company
undertakes no obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or otherwise.
CONTACT: For further information:
Glenn Silver
Lazar Partners Ltd.
(646) 871-8495
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Lumenis Ltd. via GlobeNewswire
[HUG#1955895]
Datum: 01.10.2015 - 10:00 Uhr
Sprache: Deutsch
News-ID 423947
Anzahl Zeichen: 9086
contact information:
Town:
Hertfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Lumenis Introduces the New Pulse(TM) 100H and Pulse(TM) 50H Holmium Laser Systems* Designed to Treat Any Size of Prostate and Any Size and Type of Stone"
steht unter der journalistisch-redaktionellen Verantwortung von
Lumenis Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
